Insider Buy: Molecular Templates
5:27PM ET 6/21/2022 MT NewswiresKevin M. Lalande, 10% Owner, Director, on June 13, 2022, executed a purchase for 222,000 shares in Molecular Templates (MTEM) for $198,380. Following the...
Quotes Snapshot > MTEM
Molecular Templates Inc MTEM:NASDAQ
Last Price$0.95Cboe Real-Time Last Sale as of 9:36AM ET 6/30/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.03(3.12%)
Bid (Size)$0.94 (100)
Ask (Size)$0.97 (167)
Day Low / High$0.95 - 0.95
Volume136.7 K
Read more news Recent News
--BofA Securities Downgrades Molecular Templates to Underperform From Buy, Sets Price Target at $1.50
10:43AM ET 5/27/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Stifel Adjusts Molecular Templates' Price Target to $9 From $11, Reiterates Buy Rating
8:50AM ET 5/16/2022 MT NewswiresMolecular Templates (MTEM) has an average rating of buy and price targets ranging from $4.50 to $18, according to analysts polled by Capital IQ. (MT...
-- Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q1 Revenue $8.5M
4:31PM ET 5/12/2022 MT Newswires...
View all Commentary and Analysis
Molecular Templates (MTEM) Investor Presentation - Slideshow
3:46PM ET 6/11/2022 Seeking AlphaMolecular Templates (MTEM) Investor Presentation - slideshow
9:02AM ET 3/16/2022 Seeking AlphaUsing Insiders To Avoid The Sucker's Game - And Trickle Money Back Into This Pullback
6:40PM ET 2/04/2022 Seeking AlphaMolecular Templates (MTEM) presents at 2021 Oppenheimer Healthcare Conference
4:52PM ET 9/27/2021 Seeking AlphaCompany Profile
Business DescriptionMolecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2000 and is headquartered in Austin, TX. View company web site for more details
| Address | 9301 Amberglen Boulevard Austin, Texas 78729 |
| Phone | +1.512.869.1555 |
| Number of Employees | 68 |
| Director, Chief Executive & Scientific Officer | Eric E. Poma |
| President & Chief Operating Officer | Jason S. Kim |
| CFO, Senior Vice President & Controller | Sean McLennan |
| Chief Medical Officer | Roger J. Waltzman |
Company Highlights
| Price Open | $0.95 |
| Previous Close | $0.98 |
| 52 Week Range | $0.76 - 8.29 |
| Market Capitalization | $53.3 M |
| Shares Outstanding | 56.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/11/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.38 |
| Beta vs. S&P 500 | N/A |
| Revenue | $13.3 M |
| Net Profit Margin | -177.06% |
| Return on Equity | -110.16% |
Analyst Ratings as of 05/27/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |